AVI 4557

Drug Profile

AVI 4557

Latest Information Update: 02 Jul 2009

Price : $50

At a glance

  • Originator AVI BioPharma
  • Class Antisense oligonucleotides
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 24 Oct 2006 A clinical study has been added to the pharmacokinetics section
  • 20 Jun 2006 This compound is still in active development
  • 07 Mar 2005 Phase-II clinical trials in Undefined (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top